Press Release: ImClone Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival

ImClone Systems Incorporated Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients NEW YORK -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced detailed results from the EPIC study – a randomized, open-label, multi-center Phase III trial – comparing ERBITUX® (Cetuximab) plus irinotecan to irinotecan alone in patients with metastatic colorectal cancer (mCRC) who failed first-line therapy. Results showed that the secondary endpoints of progression-free survival and response rate were significantly higher in the ERBITUX-irinotecan arm. The median time of survival without disease progression was improved by 54% in the patients who received ERBITUX plus irinotecan. This benefit produced a significant 31% reduction in the risk of disease progression (Hazard ratio, 0.692; 95% CI = 0.617– 0.776; p